We recently reported the potential for increasing the therapeutic effectiveness of HSP90 inhibitors by decreasing survival signaling and enhancing the apoptotic response in BAX+/− HCT116 colon tumor xenografts by co-administration of TRAIL [43]. Here, BAX is linked to colonic neoplasm.